IntegriChain is a proud silver sponsor and exhibitor at this year’s Asembia Specialty Pharmacy Summit, April 26 – 30, 2026 at the Wynn & Encore in Las Vegas. We look forward to welcoming attendees during the show at Booth #1608 to discuss the ways IntegriChain utilizes data, technology, consulting and managed services to drive net revenue performance, from strategy to operational execution.

Date/Time: Monday, April 27 at 3:00 PM

Session: State of Direct to Patient for Specialty

Speakers: Bill Roth, SVP & Managing Partner, Consulting & Advisory | Rich Prest, Senior Principal | Evan Benkert, Principal Consultant

Description: While first impressions lead to discounting Direct to Patient as a plausible area of Direct To Patient (DTP), when we see the situation play out, it does work. We have only seen a handful of examples because, to a great degree, the Specialty area hasn’t seen the type of patient expiries and losses of exclusivity (LOE) that General Medicine has seen. This session intends to describe where, why and how DTP will apply to Specialty. With approximately $230B of Specialty Products set to go LOE through 2030, we can start to see more examples where product is priced to Cash Pay/Self Pay/DTP at rates in the $20-30/month to rates that are not as aggressive and rather price at a discount to the higher deductible plans on the market. With the removal of utilization barriers, DTP can and will be very attractive for many products.